The clinical impacts of Roxadustat in CKD5 patients with heart failure have not yet been fully investigated thus far and remain unclear. Nevertheless, these risks are not exclusive to Roxadustat, as EPO is known to carry an increased risk of congestive heart failure as well as other thrombotic events [27-28]. This evidence concerns the gene EPO and heart failure.